{"ATC Code":"J05AG01","Abbreviation":"","Aliases":["Viramune","BI-RG-587","Nevirapine anhydrous","11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one","Viramune XR","BIRG 0587","BIRG587","Nevirapine, anhydrous","Nevirapine teva","11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one"],"Biological Half-Life":"45 hours","CAS":"129618-40-2","ChEBI":"CHEBI:63613","ChEMBL":"CHEMBL57","ChemicalClasses":[],"Chirality":"achiral","Classes":null,"Color/Form":"Crystals from pyridine and water","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; Reverse Transcriptase Inhibitors","Drug Indication":"For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.","Drug Warnings":"Severe, life-threatening, and in some cases fatal hepatotoxicity, including fulminant and cholestatic hepatitis (e.g., transaminase elevations with or without hyperbilirubinemia, prolonged partial thromboplastin time, or eosinophilia), hepatic necrosis, and hepatic failure, have been reported in patients receiving nevirapine. Although clinical presentation varied, frequently occurring features included nonspecific prodromal signs and symptoms of fatigue, malaise, anorexia, nausea, jaundice, liver tenderness, and/or hepatomegaly, with or without initially abnormal serum transaminase concentrations; a diagnosis of hepatotoxicity should be considered even if liver function tests are initially normal or alternative diagnoses are possible. Manifestations progressed over several days to hepatic failure with transaminase elevation, with or without hyperbilirubinemia, prolonged partial thromboplastin time, and/or eosinophilia. ... If nevirapine is discontinued because of hepatitis, it should be permanently discontinued and not reinitiated.","DrugClasses":[],"EliminationHalfLife":"45 hours","European Community (EC) Number":"603-345-0","FDA Pharmacological Classification":"99DK7FVK1H","FullSalts":["Nevirapine hemihydrate"],"HMDB ID":"HMDB0014383","HeavyAtomCount":20,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; Reverse Transcriptase Inhibitors","IUPACName":"2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one","Impurities":["5,11-dihydro-6h-11-propyl-4-methyl-dipyrido(3,2-b:2',3'-e) (1,4)diazepin-6-one","5,11-dihydro-6h-11-ethyl-4-methyl-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one","11-descyclopropyl nevirapine"],"InChI":"InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)","InChIKey":"NQDJXKOVJZTUJA-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)","Melting Point":"247-249 °C","MolecularFormula":"C\u003csub\u003e15\u003c/sub\u003eH\u003csub\u003e14\u003c/sub\u003eN\u003csub\u003e4\u003c/sub\u003eO","MolecularWeight":"266.30 g/mol","Pharmacodynamics":"Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time.","Physical Description":"Solid","PrevSalts":["hemihydrate"],"PubChemId":4463,"Record Description":["Nevirapine is a dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection. It has a role as an antiviral drug and a HIV-1 reverse transcriptase inhibitor. It is a dipyridodiazepine and a member of cyclopropanes.","Nevirapine is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV in adults, children, and infants. Nevirapine comes in three different forms: immediate-release tablets, oral suspension (a liquid), and extended-release tablets. The immediate-release tablet and liquid forms of nevirapine are approved for use in adults, children, and infants. The extended-release tablets are approved for use in adults and in children 6 years of age and older who meet certain height and weight requirements. Nevirapine is always used in combination with other HIV medicines.","A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.","Nevirapine is a Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor. The mechanism of action of nevirapine is as a Non-Nucleoside Reverse Transcriptase Inhibitor, and Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer.","Nevirapine is a nonnucleoside reverse transcriptase inhibitor used in combination with other agents in the therapy of human immunodeficiency virus (HIV) infection and the acquired immune deficiency syndrome (AIDS). Nevirapine is associated with a high rate of serum aminotransferase elevations during therapy and is a well established cause of acute, clinically apparent liver injury.","Nevirapine has been reported in Stachybotrys chartarum with data available.","Nevirapine is a benzodiazepine non-nucleoside reverse transcriptase inhibitor. In combination with other antiretroviral drugs, nevirapine reduces HIV viral loads and increases CD4 counts, thereby retarding or preventing the damage to the immune system and reducing the risk of developing AIDS.","NEVIRAPINE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA.","A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.","See also: Nevirapine Hemihydrate (active moiety of); Lamivudine; stavudine; nevirapine (component of); Lamivudine; zidovudine; nevirapine (component of) ... View More ...","Nevirapine is a dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection. It has a role as an antiviral drug and a HIV-1 reverse transcriptase inhibitor. It is a dipyridodiazepine and a member of cyclopropanes.","LiverTox|Antimicrobial|Antiviral: HIV|NNRTI"],"RefCount":4,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Nevirapine","Name":"Nevirapine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q263713","Name":"Nevirapine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00238","Name":"Nevirapine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/4463","Name":"Nevirapine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL57","Name":"Nevirapine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63613","Name":"Nevirapine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=129618-40-2","Name":"Nevirapine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014383","Name":"Nevirapine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07263","Name":"Nevirapine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/99DK7FVK1H","Name":"Nevirapine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID7031797","Name":"Nevirapine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 4463, Nevirapine. Accessed July 4, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/4463\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/4463\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Nevirapine. UNII: 99DK7FVK1H. Global Substance Registration System. Accessed July 4, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/99DK7FVK1H\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/99DK7FVK1H\u003c/a\u003e","Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. June 21, 2022. Accessed July 4, 2025. \u003ca href=https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017\u003ehttps://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017\u003c/a\u003e"],"SMILES":"CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4","Salts":["hemihydrate"],"SaltsAcidCount":[0],"SaltsAmineCount":[2],"SaltsUNII":["B7XF2TD73C"],"Scheduling":[{"gov":"Australia","ref":["3"],"schedule":"S4 substance"},{"gov":"United States","ref":[],"schedule":"prescription only substance"},{"gov":"European Union","ref":[],"schedule":"prescription only substance"}],"Solubility":"\u003e39.9 [ug/mL] (The mean of the results at pH 7.4)","StoreUNII":["99DK7FVK1H"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="83.998mm" version="1.2" viewBox="0 0 74.387 83.998" width="74.387mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="84.0" stroke="none" width="75.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="40.979" x2="49.561" y1="1.046" y2="13.64"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line x1="49.561" x2="42.945" y1="13.64" y2="27.37"/>
                        
                <line x1="51.147" x2="45.753" y1="15.967" y2="27.16"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd3" x1="42.945" x2="51.526" y1="27.37" y2="39.963"/>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="51.526" x2="63.387" y1="39.963" y2="39.078"/>
                        
                <line x1="52.749" x2="63.206" y1="37.427" y2="36.646"/>
                      
                <line class="hi" stroke="#3050F8" x1="63.387" x2="57.456500000000005" y1="39.078" y2="39.5205"/>
                <line class="hi" stroke="#3050F8" x1="63.206" x2="57.977500000000006" y1="36.646" y2="37.036500000000004"/>
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="68.513" x2="73.341" y1="35.118" y2="25.1"/>
                  
            <g class="bond" id="mol1bnd6">
                        
                <line x1="73.341" x2="64.759" y1="25.1" y2="12.506"/>
                        
                <line x1="70.533" x2="63.537" y1="25.31" y2="15.042"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd7" x1="49.561" x2="64.759" y1="13.64" y2="12.506"/>
                  
            <line class="bond" id="mol1bnd8" x1="51.526" x2="48.201" y1="39.963" y2="50.736"/>
                  
            <line class="bond" id="mol1bnd9" x1="43.787" x2="32.845" y1="55.797" y2="60.091"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="32.845" x2="19.642" y1="60.091" y2="52.463"/>
                        
                <line x1="30.407" x2="19.642" y1="61.499" y2="55.279"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="19.642" x2="6.444" y1="52.463" y2="60.083"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="6.444" x2="6.449" y1="60.083" y2="75.331"/>
                        
                <line x1="8.883" x2="8.887" y1="61.49" y2="73.924"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="6.449" x2="19.652" y1="75.331" y2="82.96"/>
                  
            <g class="bond" id="mol1bnd14">
                        
                <line x1="19.652" x2="29.697" y1="82.96" y2="77.16"/>
                        
                <line x1="19.652" x2="28.477" y1="80.144" y2="75.048"/>
                      
                <line class="hi" stroke="#3050F8" x1="29.697" x2="24.674500000000002" y1="77.16" y2="80.06"/>
                <line class="hi" stroke="#3050F8" x1="28.477" x2="24.064500000000002" y1="75.048" y2="77.596"/>
            </g>
                  
            <line class="bond" id="mol1bnd15" x1="32.845" x2="32.849" y1="60.091" y2="71.49"/>
                  
            <line class="bond" id="mol1bnd16" x1="19.642" x2="17.38" y1="52.463" y2="37.392"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="17.581" x2="6.056" y1="38.73" y2="35.169"/>
                        
                <line x1="18.301" x2="6.776" y1="36.4" y2="32.839"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="6.056000000000001" x2="11.8185" y1="35.169" y2="36.9495"/>
                <line class="hi" stroke="#FF0D0D" x1="6.776" x2="12.538499999999999" y1="32.839" y2="34.6195"/>
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="17.38" x2="24.856" y1="37.392" y2="29.341"/>
                  
            <line class="bond" id="mol1bnd19" x1="42.945" x2="31.087" y1="27.37" y2="26.477"/>
                  
            <line class="bond" id="mol1bnd20" x1="49.998" x2="58.202" y1="57.278" y2="64.891"/>
                  
            <line class="bond" id="mol1bnd21" x1="58.202" x2="62.692" y1="64.891" y2="79.463"/>
                  
            <line class="bond" id="mol1bnd22" x1="62.692" x2="73.06" y1="79.463" y2="68.282"/>
                  
            <line class="bond" id="mol1bnd23" x1="58.202" x2="73.06" y1="64.891" y2="68.282"/>
                  
            <path class="atom" d="M68.665 41.279h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.578v4.9z" id="mol1atm5" stroke="none"/>
                  
            <path class="atom" d="M48.972 56.974h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.608 4.054h.029q-.006 -.107 -.018 -.327q-.011 -.22 -.023 -.476q-.006 -.262 -.006 -.483v-2.768h.577v4.9z" id="mol1atm8" stroke="none"/>
                  
            <path class="atom" d="M34.791 77.789h-.721l-2.619 -4.066h-.03q.012 .238 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm14" stroke="none"/>
                  
            <path class="atom" d="M5.078 32.889q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM1.215 32.889q-.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.928 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .524 -.393 1.452z" fill="#FF0D0D" id="mol1atm16" stroke="none"/>
                  
            <g class="atom" id="mol1atm17">
                        
                <path d="M29.69 28.675h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .358 .023 .733v2.738h-.565v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" stroke="none"/>
                        
                <path d="M29.553 23.214h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.071h2.512v-2.071h.619v4.899z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="68.513" x2="70.92699999999999" y1="35.118" y2="30.109"/>
            <line class="hi" id="mol1bnd8" stroke="#3050F8" x1="48.201" x2="49.8635" y1="50.736" y2="45.3495"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="43.787" x2="38.316" y1="55.797" y2="57.944"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="32.849" x2="32.846999999999994" y1="71.49" y2="65.7905"/>
            <line class="hi" id="mol1bnd18" stroke="#3050F8" x1="24.856" x2="21.118000000000002" y1="29.341" y2="33.3665"/>
            <line class="hi" id="mol1bnd18" stroke="#3050F8" x1="24.856" x2="21.118000000000002" y1="29.341" y2="33.3665"/>
            <line class="hi" id="mol1bnd19" stroke="#3050F8" x1="31.087" x2="37.016" y1="26.477" y2="26.9235"/>
            <line class="hi" id="mol1bnd19" stroke="#3050F8" x1="31.087" x2="37.016" y1="26.477" y2="26.9235"/>
            <line class="hi" id="mol1bnd20" stroke="#3050F8" x1="49.998" x2="54.099999999999994" y1="57.278" y2="61.084500000000006"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Therapeutic Uses":"Nevirapine is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection. Drug-resistant HIV emerges rapidly and uniformly when nevirapine is administered as monotherapy. Therefore, nevirapine should always be administered in combination with at least two other antiretroviral agents when it is used for the treatment of HIV-1 infection. /Included in US product labeling/","Title":"Nevirapine","UNII":"99DK7FVK1H","Wikidata":"Q263713","Wikipedia":"Nevirapine","XLogP":2}